A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma
Completed · Phase 2 · NCT05909904
Conditions: Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
At a glance
- Research payments reported, 2025
- $401,720
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 160
About the trial
- Sponsor
- BeiGene
- Tested
- Tislelizumab (drug), BGB-A425 (drug), LBL-007 (drug)
- Dates
- Started 2023-08-02; completion 2026-07-23
- Results posted
- Yes
This study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
From ClinicalTrials.gov, last updated 2026-09-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines Ltd. reported $401,720 in research payments for this study in 2025 (59 payments).
Products named: Tevimbra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Saad Munib Ahmed Khan, MD Medical Oncology · Stanford, CA
- Robert M. Jotte, MD Hematology & Oncology · Lone Tree, CO
- Cesar A. Perez Batista, M.D. Medical Oncology · Orlando, FL
- Jessica A. Hellyer Medical Oncology · Philadelphia, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Texas Oncology-Amarillo Cancer Center $154,092
- The Board of Trustees of the Leland Stanford Junior University $124,829
- Cancer Care Northwest Centers, Ps $71,585
- Florida Cancer Specialist (scri) - Fort Myers $51,213
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.